Current Illinois CancerCare Clinical Trials

CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

Study Number: NSABP C-14

Study Summary:
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.

Status: Open

Study Coordinator(s)
  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Amanda , 309-243-3663, amullery@illinoiscancercare.com

Study Link

« Search Again